PROSTALUND AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.57 SEK | +0.71% |
|
-9.52% | -65.03% |
| 16/05 | ProstaLund AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 08/04 | ProstaLund AB Presents Two New Studies with Schelin Catheter | CI |
ProstaLund AB is a Sweden-based company that provides health care products and services. The Company develops and manufactures urological devices and treatments primarily for benign prostatic hyperplasia (BPH). The Company develops CoreTherm, a patented Thermotherapy treatment method for BPH, which takes approximately 6-15 minutes and offers long-term symptom relief. CoreTherm is used in hospitals and clinics in Sweden and worldwide.
Calendar
30/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -65.03% | 4.07M | |
| -5.56% | 181B | |
| -0.11% | 108B | |
| -6.17% | 66.12B | |
| +2.64% | 50.65B | |
| +6.58% | 43.11B | |
| +3.40% | 41.3B | |
| +21.98% | 31.6B | |
| +16.81% | 25.03B | |
| -5.81% | 24.16B |
- Stock Market
- Equities
- PLUN Stock
- News ProstaLund AB
- ProstaLund Up 12% With Swiss Approval for Schelin Catheter
